ICON Public (NASDAQ:ICLR) Price Target Lowered to $330.00 at Evercore ISI

ICON Public (NASDAQ:ICLR) had its price target decreased by Evercore ISI from $350.00 to $330.00 in a research note released on Friday morning, Benzinga reports. Evercore ISI currently has an outperform rating on the medical research company’s stock.

Several other brokerages also recently weighed in on ICLR. Barclays lifted their price objective on shares of ICON Public from $325.00 to $355.00 and gave the company an overweight rating in a research report on Friday, February 23rd. Mizuho restated a buy rating and set a $346.00 price target on shares of ICON Public in a research report on Thursday, April 4th. Robert W. Baird boosted their price target on shares of ICON Public from $362.00 to $363.00 and gave the stock an outperform rating in a research report on Friday. Truist Financial boosted their price target on shares of ICON Public from $357.00 to $367.00 and gave the stock a buy rating in a research report on Friday, February 23rd. Finally, TD Cowen boosted their price target on shares of ICON Public from $343.00 to $349.00 and gave the stock a buy rating in a research report on Friday. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of Moderate Buy and an average target price of $321.64.

ICON Public Trading Up 2.7 %

ICON Public stock opened at $308.31 on Friday. The firm’s 50-day moving average is $318.89 and its 200-day moving average is $282.81. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.21 and a current ratio of 1.21. ICON Public has a 1 year low of $181.92 and a 1 year high of $344.77. The company has a market cap of $25.44 billion, a P/E ratio of 37.51, a PEG ratio of 1.42 and a beta of 1.15.

ICON Public (NASDAQ:ICLR) last issued its quarterly earnings data on Wednesday, February 21st. The medical research company reported $3.40 earnings per share for the quarter, beating the consensus estimate of $3.27 by $0.13. The firm had revenue of $2.07 billion for the quarter, compared to the consensus estimate of $2.08 billion. ICON Public had a net margin of 8.30% and a return on equity of 11.70%. On average, equities analysts expect that ICON Public will post 14.4 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Bruce G. Allen Investments LLC acquired a new position in ICON Public in the 4th quarter valued at $25,000. Livelsberger Financial Advisory acquired a new position in ICON Public in the 4th quarter valued at $29,000. Pinnacle Bancorp Inc. grew its stake in ICON Public by 110.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 105 shares of the medical research company’s stock valued at $30,000 after buying an additional 55 shares during the last quarter. Riverview Trust Co acquired a new position in ICON Public in the 1st quarter valued at $31,000. Finally, GAMMA Investing LLC acquired a new position in ICON Public in the 4th quarter valued at $37,000. 95.61% of the stock is owned by hedge funds and other institutional investors.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.